Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico

60 Páginas.

Autores:
Aulestia Baldeón, Elcie Carolina
Tipo de recurso:
Fecha de publicación:
2013
Institución:
Universidad de la Sabana
Repositorio:
Repositorio Universidad de la Sabana
Idioma:
spa
OAI Identifier:
oai:intellectum.unisabana.edu.co:10818/9372
Acceso en línea:
http://hdl.handle.net/10818/9372
Palabra clave:
Prolatina -- Investigaciones
Estradiol
Lupus eritematoso cutáneo -- Piel -- Enfermedades
Rights
License
http://purl.org/coar/access_right/c_abf2
id REPOUSABA2_92289c5dc144b467be7d24fb768e906c
oai_identifier_str oai:intellectum.unisabana.edu.co:10818/9372
network_acronym_str REPOUSABA2
network_name_str Repositorio Universidad de la Sabana
repository_id_str
dc.title.es_CO.fl_str_mv Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
title Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
spellingShingle Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
Prolatina -- Investigaciones
Estradiol
Lupus eritematoso cutáneo -- Piel -- Enfermedades
title_short Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
title_full Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
title_fullStr Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
title_full_unstemmed Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
title_sort Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico
dc.creator.fl_str_mv Aulestia Baldeón, Elcie Carolina
dc.contributor.advisor.none.fl_str_mv Granados, Carlos Eduardo
Zubiría, Alberto de
dc.contributor.author.none.fl_str_mv Aulestia Baldeón, Elcie Carolina
dc.subject.none.fl_str_mv Prolatina -- Investigaciones
Estradiol
Lupus eritematoso cutáneo -- Piel -- Enfermedades
topic Prolatina -- Investigaciones
Estradiol
Lupus eritematoso cutáneo -- Piel -- Enfermedades
description 60 Páginas.
publishDate 2013
dc.date.accessioned.none.fl_str_mv 2013-12-16T17:54:36Z
dc.date.available.none.fl_str_mv 2013-12-16T17:54:36Z
dc.date.created.none.fl_str_mv 2013
dc.date.issued.none.fl_str_mv 2013-12-16
dc.type.none.fl_str_mv bachelorThesis
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv Tesis de especialización
dc.type.hasVersion.none.fl_str_mv publishedVersion
dc.identifier.citation.none.fl_str_mv Clowse MEB. Lupus activity in pregnancy. Rheum. Dis. Clin. North Am. 2007 May;33(2):237–252, v.
Kotzin BL. Systemic lupus erythematosus. Cell. 1996 May;85(3):303–6.
Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum. Dis. Clin. North Am. 2005 Feb;31(1):161–175, x
Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–8.
Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008 May;17(5):412–5
Crow MK. Developments in the clinical understanding of lupus. Arthritis Res. Ther. 2009;11(5):245.
Cabrera JMA, D CAC, S RC, V PAC. Autoinmunidad y enfermedad autoinmune. Corporación para Investigaciones Biológicas; 2005. p. 557.
Lim SS, Drenkard C. Epidemiology of systemic lupus erythematosus: capturing the butterfly. Curr. Rheumatol. Rep. 2008 Aug;10(4):265–72
Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010 Feb;39(4):257–68.
Tikly M, Navarra S V. Lupus in the developing world--is it any different? Best Pract. Res. Clin. Rheumatol. 2008 Aug;22(4):643–55.
Vasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):1–13, vii.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7.
Crow MK. MD Consult: Goldman: Cecil Medicine, 23rd ed. [Internet]. 2007 [cited 2011 Jan 15]. Available from: http://www.mdconsult.com/books/page
Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937–44.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–40.
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol. 1994 Aug;21(8):1468–71.
Ramsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemi. Arthritis Rheum. 2003;49(S5):S225–S233.
Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 1988 Nov;69(259):927–37.
Rogerio A. Lobo. MD Consult: Katz: Comprehensive Gynecology, Chapter 4 – Reproductive Endocrinology : Neuroendocrinology, Gonadotropins, Sex Steroids, Prostaglandins, Ovulation, Menstruation, Hormone Assay. Ovarian Steroids [Internet]. 2007 [cited 2011 Jan 16]. Available from: http://www.mdconsult.com/books
Demura R, Suzuki T, Tajima S, Mitsuhashi S, Odagiri E, Demura H, et al. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab. 1993 Apr;76(4):1080–2.
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med. 2002 Jan;346(5):340–52
Cohen-Solal JFG, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 2006;305:67–88.
Edward Rose, Donald Pillsbury. LUPUS ERYTHEMATOSUS (ERYTHEMATODES) AND OVARIAN FUNCTION: OBSERVATIONS ON A POSSIBLE RELATIONSHIP, WITH REPORT OF SIX CASES*. 1944 Dec;21(6):1022–34
Cohen-Solal JFG, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus. 2008 Jun;17(6):528–32.
Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin. Rheumatol. 2006 Sep;18(5):456–61.
McMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003;48(8):2100–10.
Folomeev M, Dougados M, Beaune J. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992 May;1(3):191–5
Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum. 1979;22(11):1161–9.
Verthelyi D, Ansar Ahmed S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmun. 1997 Apr;10(2):115–25.
Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010 Jan;2010:1–14.
Gomez, G, Posada, G, Martinez, C. Prolactina Y Prolactinomas: Una vision global. Rev. Colomb. Menopaus. 2000;6(3):244–69
Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum. Psychopharmacol. 2010 Jun;25(4):281–97.
Guber HA, Farag AF, Tumors P. Evaluation of Endocrine Function. In: McPherson RA, Pincus MR, editors. Henry’s Clin. Diagnosis Manag. by Lab. Methods. Twenty sec. Philadelphia: Elsevier Inc.; 2011. p. 365–401.
Lobo, R. MD Consult: Katz: Comprehensive Gynecology. Chapter 39 – Hyperprolactinemia, Galactorrhea, and Pituitary Adenomas : Etiology, Differential Diagnosis, Natural History, Management. 5th ed. Mosby Elsevier; 2007.
McPherson RA, Pincus MR, Henry JB. Henry’s clinical diagnosis and management by laboratory methods. 21st ed. Saunders Elsevier; 2007. p. 1484.
SIEVERTSEN GD, LIM VS, NAKAWATASE C, FROHMAN LA. Metabolic Clearance and Secretion Rates of Human Prolactin in Normal Subjects and in Patients with Chronic Renal Failure. J Clin Endocrinol Metab. 1980 May;50(5):846–52.
Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta BioMedica Atenei Parm. 2007;78 Suppl 1:255–61.
Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol. Sci. 1989 Jan;10(1):40–4.
Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):8–15.
Jacobi a., Rohde W, Ventz M, Riemekasten G, Burmester G-R, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001 Aug 1;10(8):554–61.
Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am. J. Med. Sci. 1992 Apr;303(4):222–6.
Rovenský J, Juránková E, Rauová L, Blazícková S, Lukác J, Veselková Z, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 1997 Dec;24(12):2330–4.
Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 2009 Jun;60(6):1743– 52.
Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 2003 Jan;111(2):275–83.
Rezanka LJ, Kenny JJ, Longo DL. Dual isotype expressing B cells [[kappa](+)/[lambda](+)] arise during the ontogeny of B cells in the bone marrow of normal nontransgenic mice. Cell. Immunol. 2005 Nov;238(1):38–48.
Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 2005 Mar 1;102(5):1608–13
Radic MZ, Erikson J, Litwin S, Weigert M. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 1993 Apr 1;177(4):1165–73.
Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. U. S. A. 1980 Mar;77(3):1602–6.
Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of Anergic B Cells within a Wild-Type Repertoire. Immunity. 2006;25(6):953–62.
Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 2005 Nov;6(11):1160–7
Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):50–9.
Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J. Rheumatol. 1992 Sep;19(9):1333–6.
Walker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1998 May;840:762–72.
McMurray RW. Prolactin and systemic lupus erythematosus. Ann. Med. Interne (Paris). 1996;147(4):253–8.
Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979 Nov;22(11):1195–8.
Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med. Wkly. 2010 Apr;140(13-14):187–201.0
Isenberg DA. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM .... thank you MAM. Lupus. 2007;16(11):849–51.
P. Tsao, B., Hannahs, B. Firestein: Kelley’s Textbook of Rheumatology - Part 11 Systemic Lupus Eritematosus and Related Syndromes. 8th ed. W.B. Saunders Company; 2008. p. Ch 75.
Carroll M V., Sim RB. Complement in health and disease. Adv. Drug Deliv. Rev. Elsevier B.V.; 2011 Sep 16;63(12):965–75.
Julkunen H, Ekblom-Kullberg S, Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 2011 Jun
Amezcua-Guerra LM, Springall R, Arrieta-Alvarado AA, Rodríguez V, RiveraMartinez E, Castillo-Martinez D, et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin. Lab. 2011;57(7-8):607–13.
Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):99–108, viii.
Tehseen I, Khemomal K, Shehnaz S, Khemomal K. SYSTEMIC LUPUS ERYTHEMATOSUS, FEMALE OF FERTILE AGE CHANGES IN REPRODUCTIVE HORMONES ESTROGEN AND PROLACTIN LEVELS. Prof. Med. J. 2011;18(2):255–8.
Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2008;26(3):436–41.
Tiskievicz F, Mallmann ES. Prolactina, estradiol e anticorpos anticardiolipina em amostra de mulheres pré-menopáusicas com lúpus eritematoso sistêmico: estudo-piloto. Rev Bras Reum. 2011;51(5):456–64.
Weidler C, Härle P, Schedel J, Schmidt M, Schölmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol. 2004 Mar;31(3):489–94
Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010 May;19(6):734– 40.
Dagtas A, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. 2002;109(12):1625–33
Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 Jun;20(6):785–98.
Venkatesh J, Peeva E, Xu X, Diamond B. Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J. Immunol. 2006 Mar 15;176(6):3311–4.
Rider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells. Clin. Immunol. 2000 May;95(2):124–34.
Rider V, Keltner S, Abdou NI. Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms. J. Gend. Specif. Med. 2003 Jan;6(2):14–21
Kim W-U, Min S-Y, Hwang S-H, Yoo S, Kim K-J, Cho C-S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010 Sep;161(3):453–8
Feng F, Nyland J, Banyai M, Tatum A, Silverstone AE, Gavalchin J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol. Elsevier Inc.; 2010 Feb;134(2):226–36
Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould K a. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 2008 Mar;9(2):137–52.
Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. 2001 Feb;12(2):241–51
Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol. 2002 May;160(5):1877–85.
Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol. 2003 May;162(5):1441–8.
Shim G-J, Kis LL, Warner M, Gustafsson J-A. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. U. S. A. 2004 Feb 10;101(6):1720–4.
Han HJ, Park SH, Park HJ, Park KM, Kang JW, Lee JH, et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin. Exp. Pharmacol. Physiol. 29(1- 2):60–7.
Irsik DL, Carmines PK, Lane PH. Classical Estrogen Receptors and ERα Splice Variants in the Mouse. PLoS One. 2013 Jan;8(8):e70926.
Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol. 2000 Oct;52(4):393–400.
Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 2003 Apr;62(4):341–6.
Abdou NI, Rider V, Greenwell C, Li X, Kimler BF. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J. Rheumatol. 2008 May;35(5):797.
Qu X a, Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics. 2009 Jan;10 Suppl 5:S4.
Singh MN, Martin-Hirsch PL, Martin FL. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med. Sci. Monit. 2008 Sep;14(9):RA144–8.
Rezaieyazdi Z, Hesamifard A. Correlation between serum prolactin levels and lupus activity. Rheumatol. Int. 2006 Sep;26(11):1036–9.
Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. APLAR J. Rheumatol. 2006 Sep;9(3):227–31.
Mok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br. J. Rheumatol. 1997 Sep;36(9):986–9.
Moszkorzová L, Lacinová Z, Marek J, Musilová L, Dohnalová A, Dostál C. Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2002;20(6):807–12.
Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001;10(10):748–56
Jokar M, Maybodi NT, Amini A, Fard MH. Prolactin and macroprolactin in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 2008 Sep;11(3):257–62
Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra M a. Prolactin Levels Are Associated with Lupus Activity, Lupus Anticoagulant, and Poor Outcome in Pregnancy. Ann. N. Y. Acad. Sci. 2007 Jun 1;1108(1):218–26
Karimifar M, Tahmasebi A, Bonakdar ZS, Purajam S. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol. Int. 2013 Feb;33(2):511–6
Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 1996 Apr;23(4):629–32.
Stevens a., Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus. 2001 Oct 1;10(10):676–83.
Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc. Natl. Acad. Sci. U. S. A. 1992 Aug 15;89(16):7713–6.
Yu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus. 2001;10(10):691–9.
Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997 May;215(1):35–52.
Clevenger C V, Kline JB. Prolactin receptor signal transduction. Lupus. 2001 Jan;10(10):706–18.
Dostál C, Moszkorzová L, Musilová L, Lacinová Z, Marek J, Zvárová J. Serum prolactin stress values in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2003 May;62(5):487–8.
McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 1995 Nov;22(11):2084–91.
Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Muñoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled study. Lupus. 1998;7(6):414–9.
Walker SE. Modulation of hormones in the treatment of lupus. Am. J. Manag. Care. 2001 Oct;7(16 Suppl):S486–489.
Jara LJ, Cruz-Cruz P, Saavedra M a, Medina G, García-Flores A, Angeles U, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann. N. Y. Acad. Sci. 2007 Sep;1110:297–304.
Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007 Aug;1109:385–400.
Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. Elsevier B.V.; 2012 May;11(6-7):A486–92.
Steinberg AD, Steinberg BJ. Lupus disease activity associated with menstrual cycle. J. Rheumatol. 1985 Aug;12(4):816–7.
Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002 Jan;11(3):175–80.
Medeiros PB, Febrônio M V, Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus. 2009 Jan;18(1):38–43.
Colangelo K, Haig S, Bonner A, Zelenietz C, Pope J. Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 2011 Apr;50(4):703–8
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10818/9372
dc.identifier.local.none.fl_str_mv 256511
TE06227
identifier_str_mv Clowse MEB. Lupus activity in pregnancy. Rheum. Dis. Clin. North Am. 2007 May;33(2):237–252, v.
Kotzin BL. Systemic lupus erythematosus. Cell. 1996 May;85(3):303–6.
Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum. Dis. Clin. North Am. 2005 Feb;31(1):161–175, x
Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–8.
Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008 May;17(5):412–5
Crow MK. Developments in the clinical understanding of lupus. Arthritis Res. Ther. 2009;11(5):245.
Cabrera JMA, D CAC, S RC, V PAC. Autoinmunidad y enfermedad autoinmune. Corporación para Investigaciones Biológicas; 2005. p. 557.
Lim SS, Drenkard C. Epidemiology of systemic lupus erythematosus: capturing the butterfly. Curr. Rheumatol. Rep. 2008 Aug;10(4):265–72
Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010 Feb;39(4):257–68.
Tikly M, Navarra S V. Lupus in the developing world--is it any different? Best Pract. Res. Clin. Rheumatol. 2008 Aug;22(4):643–55.
Vasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):1–13, vii.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7.
Crow MK. MD Consult: Goldman: Cecil Medicine, 23rd ed. [Internet]. 2007 [cited 2011 Jan 15]. Available from: http://www.mdconsult.com/books/page
Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937–44.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–40.
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol. 1994 Aug;21(8):1468–71.
Ramsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemi. Arthritis Rheum. 2003;49(S5):S225–S233.
Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 1988 Nov;69(259):927–37.
Rogerio A. Lobo. MD Consult: Katz: Comprehensive Gynecology, Chapter 4 – Reproductive Endocrinology : Neuroendocrinology, Gonadotropins, Sex Steroids, Prostaglandins, Ovulation, Menstruation, Hormone Assay. Ovarian Steroids [Internet]. 2007 [cited 2011 Jan 16]. Available from: http://www.mdconsult.com/books
Demura R, Suzuki T, Tajima S, Mitsuhashi S, Odagiri E, Demura H, et al. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab. 1993 Apr;76(4):1080–2.
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med. 2002 Jan;346(5):340–52
Cohen-Solal JFG, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 2006;305:67–88.
Edward Rose, Donald Pillsbury. LUPUS ERYTHEMATOSUS (ERYTHEMATODES) AND OVARIAN FUNCTION: OBSERVATIONS ON A POSSIBLE RELATIONSHIP, WITH REPORT OF SIX CASES*. 1944 Dec;21(6):1022–34
Cohen-Solal JFG, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus. 2008 Jun;17(6):528–32.
Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin. Rheumatol. 2006 Sep;18(5):456–61.
McMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003;48(8):2100–10.
Folomeev M, Dougados M, Beaune J. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992 May;1(3):191–5
Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum. 1979;22(11):1161–9.
Verthelyi D, Ansar Ahmed S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmun. 1997 Apr;10(2):115–25.
Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010 Jan;2010:1–14.
Gomez, G, Posada, G, Martinez, C. Prolactina Y Prolactinomas: Una vision global. Rev. Colomb. Menopaus. 2000;6(3):244–69
Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum. Psychopharmacol. 2010 Jun;25(4):281–97.
Guber HA, Farag AF, Tumors P. Evaluation of Endocrine Function. In: McPherson RA, Pincus MR, editors. Henry’s Clin. Diagnosis Manag. by Lab. Methods. Twenty sec. Philadelphia: Elsevier Inc.; 2011. p. 365–401.
Lobo, R. MD Consult: Katz: Comprehensive Gynecology. Chapter 39 – Hyperprolactinemia, Galactorrhea, and Pituitary Adenomas : Etiology, Differential Diagnosis, Natural History, Management. 5th ed. Mosby Elsevier; 2007.
McPherson RA, Pincus MR, Henry JB. Henry’s clinical diagnosis and management by laboratory methods. 21st ed. Saunders Elsevier; 2007. p. 1484.
SIEVERTSEN GD, LIM VS, NAKAWATASE C, FROHMAN LA. Metabolic Clearance and Secretion Rates of Human Prolactin in Normal Subjects and in Patients with Chronic Renal Failure. J Clin Endocrinol Metab. 1980 May;50(5):846–52.
Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta BioMedica Atenei Parm. 2007;78 Suppl 1:255–61.
Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol. Sci. 1989 Jan;10(1):40–4.
Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):8–15.
Jacobi a., Rohde W, Ventz M, Riemekasten G, Burmester G-R, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001 Aug 1;10(8):554–61.
Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am. J. Med. Sci. 1992 Apr;303(4):222–6.
Rovenský J, Juránková E, Rauová L, Blazícková S, Lukác J, Veselková Z, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 1997 Dec;24(12):2330–4.
Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 2009 Jun;60(6):1743– 52.
Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 2003 Jan;111(2):275–83.
Rezanka LJ, Kenny JJ, Longo DL. Dual isotype expressing B cells [[kappa](+)/[lambda](+)] arise during the ontogeny of B cells in the bone marrow of normal nontransgenic mice. Cell. Immunol. 2005 Nov;238(1):38–48.
Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 2005 Mar 1;102(5):1608–13
Radic MZ, Erikson J, Litwin S, Weigert M. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 1993 Apr 1;177(4):1165–73.
Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. U. S. A. 1980 Mar;77(3):1602–6.
Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of Anergic B Cells within a Wild-Type Repertoire. Immunity. 2006;25(6):953–62.
Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 2005 Nov;6(11):1160–7
Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):50–9.
Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J. Rheumatol. 1992 Sep;19(9):1333–6.
Walker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1998 May;840:762–72.
McMurray RW. Prolactin and systemic lupus erythematosus. Ann. Med. Interne (Paris). 1996;147(4):253–8.
Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979 Nov;22(11):1195–8.
Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med. Wkly. 2010 Apr;140(13-14):187–201.0
Isenberg DA. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM .... thank you MAM. Lupus. 2007;16(11):849–51.
P. Tsao, B., Hannahs, B. Firestein: Kelley’s Textbook of Rheumatology - Part 11 Systemic Lupus Eritematosus and Related Syndromes. 8th ed. W.B. Saunders Company; 2008. p. Ch 75.
Carroll M V., Sim RB. Complement in health and disease. Adv. Drug Deliv. Rev. Elsevier B.V.; 2011 Sep 16;63(12):965–75.
Julkunen H, Ekblom-Kullberg S, Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 2011 Jun
Amezcua-Guerra LM, Springall R, Arrieta-Alvarado AA, Rodríguez V, RiveraMartinez E, Castillo-Martinez D, et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin. Lab. 2011;57(7-8):607–13.
Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):99–108, viii.
Tehseen I, Khemomal K, Shehnaz S, Khemomal K. SYSTEMIC LUPUS ERYTHEMATOSUS, FEMALE OF FERTILE AGE CHANGES IN REPRODUCTIVE HORMONES ESTROGEN AND PROLACTIN LEVELS. Prof. Med. J. 2011;18(2):255–8.
Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2008;26(3):436–41.
Tiskievicz F, Mallmann ES. Prolactina, estradiol e anticorpos anticardiolipina em amostra de mulheres pré-menopáusicas com lúpus eritematoso sistêmico: estudo-piloto. Rev Bras Reum. 2011;51(5):456–64.
Weidler C, Härle P, Schedel J, Schmidt M, Schölmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol. 2004 Mar;31(3):489–94
Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010 May;19(6):734– 40.
Dagtas A, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. 2002;109(12):1625–33
Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 Jun;20(6):785–98.
Venkatesh J, Peeva E, Xu X, Diamond B. Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J. Immunol. 2006 Mar 15;176(6):3311–4.
Rider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells. Clin. Immunol. 2000 May;95(2):124–34.
Rider V, Keltner S, Abdou NI. Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms. J. Gend. Specif. Med. 2003 Jan;6(2):14–21
Kim W-U, Min S-Y, Hwang S-H, Yoo S, Kim K-J, Cho C-S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010 Sep;161(3):453–8
Feng F, Nyland J, Banyai M, Tatum A, Silverstone AE, Gavalchin J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol. Elsevier Inc.; 2010 Feb;134(2):226–36
Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould K a. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 2008 Mar;9(2):137–52.
Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. 2001 Feb;12(2):241–51
Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol. 2002 May;160(5):1877–85.
Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol. 2003 May;162(5):1441–8.
Shim G-J, Kis LL, Warner M, Gustafsson J-A. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. U. S. A. 2004 Feb 10;101(6):1720–4.
Han HJ, Park SH, Park HJ, Park KM, Kang JW, Lee JH, et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin. Exp. Pharmacol. Physiol. 29(1- 2):60–7.
Irsik DL, Carmines PK, Lane PH. Classical Estrogen Receptors and ERα Splice Variants in the Mouse. PLoS One. 2013 Jan;8(8):e70926.
Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol. 2000 Oct;52(4):393–400.
Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 2003 Apr;62(4):341–6.
Abdou NI, Rider V, Greenwell C, Li X, Kimler BF. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J. Rheumatol. 2008 May;35(5):797.
Qu X a, Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics. 2009 Jan;10 Suppl 5:S4.
Singh MN, Martin-Hirsch PL, Martin FL. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med. Sci. Monit. 2008 Sep;14(9):RA144–8.
Rezaieyazdi Z, Hesamifard A. Correlation between serum prolactin levels and lupus activity. Rheumatol. Int. 2006 Sep;26(11):1036–9.
Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. APLAR J. Rheumatol. 2006 Sep;9(3):227–31.
Mok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br. J. Rheumatol. 1997 Sep;36(9):986–9.
Moszkorzová L, Lacinová Z, Marek J, Musilová L, Dohnalová A, Dostál C. Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2002;20(6):807–12.
Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001;10(10):748–56
Jokar M, Maybodi NT, Amini A, Fard MH. Prolactin and macroprolactin in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 2008 Sep;11(3):257–62
Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra M a. Prolactin Levels Are Associated with Lupus Activity, Lupus Anticoagulant, and Poor Outcome in Pregnancy. Ann. N. Y. Acad. Sci. 2007 Jun 1;1108(1):218–26
Karimifar M, Tahmasebi A, Bonakdar ZS, Purajam S. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol. Int. 2013 Feb;33(2):511–6
Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 1996 Apr;23(4):629–32.
Stevens a., Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus. 2001 Oct 1;10(10):676–83.
Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc. Natl. Acad. Sci. U. S. A. 1992 Aug 15;89(16):7713–6.
Yu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus. 2001;10(10):691–9.
Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997 May;215(1):35–52.
Clevenger C V, Kline JB. Prolactin receptor signal transduction. Lupus. 2001 Jan;10(10):706–18.
Dostál C, Moszkorzová L, Musilová L, Lacinová Z, Marek J, Zvárová J. Serum prolactin stress values in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2003 May;62(5):487–8.
McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 1995 Nov;22(11):2084–91.
Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Muñoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled study. Lupus. 1998;7(6):414–9.
Walker SE. Modulation of hormones in the treatment of lupus. Am. J. Manag. Care. 2001 Oct;7(16 Suppl):S486–489.
Jara LJ, Cruz-Cruz P, Saavedra M a, Medina G, García-Flores A, Angeles U, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann. N. Y. Acad. Sci. 2007 Sep;1110:297–304.
Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007 Aug;1109:385–400.
Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. Elsevier B.V.; 2012 May;11(6-7):A486–92.
Steinberg AD, Steinberg BJ. Lupus disease activity associated with menstrual cycle. J. Rheumatol. 1985 Aug;12(4):816–7.
Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002 Jan;11(3):175–80.
Medeiros PB, Febrônio M V, Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus. 2009 Jan;18(1):38–43.
Colangelo K, Haig S, Bonner A, Zelenietz C, Pope J. Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 2011 Apr;50(4):703–8
256511
TE06227
url http://hdl.handle.net/10818/9372
dc.language.iso.es_CO.fl_str_mv spa
language spa
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://purl.org/coar/access_right/c_abf2
dc.publisher.none.fl_str_mv Universidad de La Sabana
dc.publisher.program.none.fl_str_mv Especialización en Medicina Interna
dc.publisher.department.none.fl_str_mv Facultad de Medicina
publisher.none.fl_str_mv Universidad de La Sabana
dc.source.none.fl_str_mv Universidad de La Sabana
Intellectum Repositorio Universidad de La Sabana
institution Universidad de la Sabana
bitstream.url.fl_str_mv https://intellectum.unisabana.edu.co/bitstream/10818/9372/2/license.txt
https://intellectum.unisabana.edu.co/bitstream/10818/9372/5/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20%28Carta%201%29.pdf
https://intellectum.unisabana.edu.co/bitstream/10818/9372/6/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20%28Carta%202%29.pdf
https://intellectum.unisabana.edu.co/bitstream/10818/9372/3/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20FINAL.pdf
https://intellectum.unisabana.edu.co/bitstream/10818/9372/4/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20FINAL.pdf.txt
bitstream.checksum.fl_str_mv f52a2cfd4df262e08e9b300d62c85cab
8c7a67cd6fc21883c8de7aba8a3c39f0
5d106558e1607a577e96767539702247
818da8cdd6d65332dcb9ff9bf061f758
173796950fb380beab4a5451d5eb6a18
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Intellectum Universidad de la Sabana
repository.mail.fl_str_mv contactointellectum@unisabana.edu.co
_version_ 1811952233618604032
spelling Granados, Carlos EduardoZubiría, Alberto deAulestia Baldeón, Elcie CarolinaEspecialista en Medicina Interna2013-12-16T17:54:36Z2013-12-16T17:54:36Z20132013-12-16Clowse MEB. Lupus activity in pregnancy. Rheum. Dis. Clin. North Am. 2007 May;33(2):237–252, v.Kotzin BL. Systemic lupus erythematosus. Cell. 1996 May;85(3):303–6.Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum. Dis. Clin. North Am. 2005 Feb;31(1):161–175, xNikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–8.Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008 May;17(5):412–5Crow MK. Developments in the clinical understanding of lupus. Arthritis Res. Ther. 2009;11(5):245.Cabrera JMA, D CAC, S RC, V PAC. Autoinmunidad y enfermedad autoinmune. Corporación para Investigaciones Biológicas; 2005. p. 557.Lim SS, Drenkard C. Epidemiology of systemic lupus erythematosus: capturing the butterfly. Curr. Rheumatol. Rep. 2008 Aug;10(4):265–72Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010 Feb;39(4):257–68.Tikly M, Navarra S V. Lupus in the developing world--is it any different? Best Pract. Res. Clin. Rheumatol. 2008 Aug;22(4):643–55.Vasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):1–13, vii.Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7.Crow MK. MD Consult: Goldman: Cecil Medicine, 23rd ed. [Internet]. 2007 [cited 2011 Jan 15]. Available from: http://www.mdconsult.com/books/pagePetri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937–44.Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–40.Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol. 1994 Aug;21(8):1468–71.Ramsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemi. Arthritis Rheum. 2003;49(S5):S225–S233.Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 1988 Nov;69(259):927–37.Rogerio A. Lobo. MD Consult: Katz: Comprehensive Gynecology, Chapter 4 – Reproductive Endocrinology : Neuroendocrinology, Gonadotropins, Sex Steroids, Prostaglandins, Ovulation, Menstruation, Hormone Assay. Ovarian Steroids [Internet]. 2007 [cited 2011 Jan 16]. Available from: http://www.mdconsult.com/booksDemura R, Suzuki T, Tajima S, Mitsuhashi S, Odagiri E, Demura H, et al. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab. 1993 Apr;76(4):1080–2.Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med. 2002 Jan;346(5):340–52Cohen-Solal JFG, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 2006;305:67–88.Edward Rose, Donald Pillsbury. LUPUS ERYTHEMATOSUS (ERYTHEMATODES) AND OVARIAN FUNCTION: OBSERVATIONS ON A POSSIBLE RELATIONSHIP, WITH REPORT OF SIX CASES*. 1944 Dec;21(6):1022–34Cohen-Solal JFG, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus. 2008 Jun;17(6):528–32.Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin. Rheumatol. 2006 Sep;18(5):456–61.McMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003;48(8):2100–10.Folomeev M, Dougados M, Beaune J. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992 May;1(3):191–5Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum. 1979;22(11):1161–9.Verthelyi D, Ansar Ahmed S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmun. 1997 Apr;10(2):115–25.Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010 Jan;2010:1–14.Gomez, G, Posada, G, Martinez, C. Prolactina Y Prolactinomas: Una vision global. Rev. Colomb. Menopaus. 2000;6(3):244–69Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum. Psychopharmacol. 2010 Jun;25(4):281–97.Guber HA, Farag AF, Tumors P. Evaluation of Endocrine Function. In: McPherson RA, Pincus MR, editors. Henry’s Clin. Diagnosis Manag. by Lab. Methods. Twenty sec. Philadelphia: Elsevier Inc.; 2011. p. 365–401.Lobo, R. MD Consult: Katz: Comprehensive Gynecology. Chapter 39 – Hyperprolactinemia, Galactorrhea, and Pituitary Adenomas : Etiology, Differential Diagnosis, Natural History, Management. 5th ed. Mosby Elsevier; 2007.McPherson RA, Pincus MR, Henry JB. Henry’s clinical diagnosis and management by laboratory methods. 21st ed. Saunders Elsevier; 2007. p. 1484.SIEVERTSEN GD, LIM VS, NAKAWATASE C, FROHMAN LA. Metabolic Clearance and Secretion Rates of Human Prolactin in Normal Subjects and in Patients with Chronic Renal Failure. J Clin Endocrinol Metab. 1980 May;50(5):846–52.Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta BioMedica Atenei Parm. 2007;78 Suppl 1:255–61.Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol. Sci. 1989 Jan;10(1):40–4.Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):8–15.Jacobi a., Rohde W, Ventz M, Riemekasten G, Burmester G-R, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001 Aug 1;10(8):554–61.Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am. J. Med. Sci. 1992 Apr;303(4):222–6.Rovenský J, Juránková E, Rauová L, Blazícková S, Lukác J, Veselková Z, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 1997 Dec;24(12):2330–4.Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 2009 Jun;60(6):1743– 52.Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 2003 Jan;111(2):275–83.Rezanka LJ, Kenny JJ, Longo DL. Dual isotype expressing B cells [[kappa](+)/[lambda](+)] arise during the ontogeny of B cells in the bone marrow of normal nontransgenic mice. Cell. Immunol. 2005 Nov;238(1):38–48.Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 2005 Mar 1;102(5):1608–13Radic MZ, Erikson J, Litwin S, Weigert M. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 1993 Apr 1;177(4):1165–73.Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. U. S. A. 1980 Mar;77(3):1602–6.Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of Anergic B Cells within a Wild-Type Repertoire. Immunity. 2006;25(6):953–62.Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 2005 Nov;6(11):1160–7Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):50–9.Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J. Rheumatol. 1992 Sep;19(9):1333–6.Walker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1998 May;840:762–72.McMurray RW. Prolactin and systemic lupus erythematosus. Ann. Med. Interne (Paris). 1996;147(4):253–8.Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979 Nov;22(11):1195–8.Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med. Wkly. 2010 Apr;140(13-14):187–201.0Isenberg DA. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM .... thank you MAM. Lupus. 2007;16(11):849–51.P. Tsao, B., Hannahs, B. Firestein: Kelley’s Textbook of Rheumatology - Part 11 Systemic Lupus Eritematosus and Related Syndromes. 8th ed. W.B. Saunders Company; 2008. p. Ch 75.Carroll M V., Sim RB. Complement in health and disease. Adv. Drug Deliv. Rev. Elsevier B.V.; 2011 Sep 16;63(12):965–75.Julkunen H, Ekblom-Kullberg S, Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 2011 JunAmezcua-Guerra LM, Springall R, Arrieta-Alvarado AA, Rodríguez V, RiveraMartinez E, Castillo-Martinez D, et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin. Lab. 2011;57(7-8):607–13.Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):99–108, viii.Tehseen I, Khemomal K, Shehnaz S, Khemomal K. SYSTEMIC LUPUS ERYTHEMATOSUS, FEMALE OF FERTILE AGE CHANGES IN REPRODUCTIVE HORMONES ESTROGEN AND PROLACTIN LEVELS. Prof. Med. J. 2011;18(2):255–8.Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2008;26(3):436–41.Tiskievicz F, Mallmann ES. Prolactina, estradiol e anticorpos anticardiolipina em amostra de mulheres pré-menopáusicas com lúpus eritematoso sistêmico: estudo-piloto. Rev Bras Reum. 2011;51(5):456–64.Weidler C, Härle P, Schedel J, Schmidt M, Schölmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol. 2004 Mar;31(3):489–94Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010 May;19(6):734– 40.Dagtas A, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. 2002;109(12):1625–33Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 Jun;20(6):785–98.Venkatesh J, Peeva E, Xu X, Diamond B. Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J. Immunol. 2006 Mar 15;176(6):3311–4.Rider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells. Clin. Immunol. 2000 May;95(2):124–34.Rider V, Keltner S, Abdou NI. Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms. J. Gend. Specif. Med. 2003 Jan;6(2):14–21Kim W-U, Min S-Y, Hwang S-H, Yoo S, Kim K-J, Cho C-S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010 Sep;161(3):453–8Feng F, Nyland J, Banyai M, Tatum A, Silverstone AE, Gavalchin J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol. Elsevier Inc.; 2010 Feb;134(2):226–36Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould K a. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 2008 Mar;9(2):137–52.Potier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. 2001 Feb;12(2):241–51Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol. 2002 May;160(5):1877–85.Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol. 2003 May;162(5):1441–8.Shim G-J, Kis LL, Warner M, Gustafsson J-A. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. U. S. A. 2004 Feb 10;101(6):1720–4.Han HJ, Park SH, Park HJ, Park KM, Kang JW, Lee JH, et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin. Exp. Pharmacol. Physiol. 29(1- 2):60–7.Irsik DL, Carmines PK, Lane PH. Classical Estrogen Receptors and ERα Splice Variants in the Mouse. PLoS One. 2013 Jan;8(8):e70926.Wu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol. 2000 Oct;52(4):393–400.Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 2003 Apr;62(4):341–6.Abdou NI, Rider V, Greenwell C, Li X, Kimler BF. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J. Rheumatol. 2008 May;35(5):797.Qu X a, Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics. 2009 Jan;10 Suppl 5:S4.Singh MN, Martin-Hirsch PL, Martin FL. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med. Sci. Monit. 2008 Sep;14(9):RA144–8.Rezaieyazdi Z, Hesamifard A. Correlation between serum prolactin levels and lupus activity. Rheumatol. Int. 2006 Sep;26(11):1036–9.Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. APLAR J. Rheumatol. 2006 Sep;9(3):227–31.Mok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br. J. Rheumatol. 1997 Sep;36(9):986–9.Moszkorzová L, Lacinová Z, Marek J, Musilová L, Dohnalová A, Dostál C. Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2002;20(6):807–12.Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001;10(10):748–56Jokar M, Maybodi NT, Amini A, Fard MH. Prolactin and macroprolactin in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 2008 Sep;11(3):257–62Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra M a. Prolactin Levels Are Associated with Lupus Activity, Lupus Anticoagulant, and Poor Outcome in Pregnancy. Ann. N. Y. Acad. Sci. 2007 Jun 1;1108(1):218–26Karimifar M, Tahmasebi A, Bonakdar ZS, Purajam S. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol. Int. 2013 Feb;33(2):511–6Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 1996 Apr;23(4):629–32.Stevens a., Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus. 2001 Oct 1;10(10):676–83.Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc. Natl. Acad. Sci. U. S. A. 1992 Aug 15;89(16):7713–6.Yu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus. 2001;10(10):691–9.Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997 May;215(1):35–52.Clevenger C V, Kline JB. Prolactin receptor signal transduction. Lupus. 2001 Jan;10(10):706–18.Dostál C, Moszkorzová L, Musilová L, Lacinová Z, Marek J, Zvárová J. Serum prolactin stress values in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2003 May;62(5):487–8.McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 1995 Nov;22(11):2084–91.Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Muñoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled study. Lupus. 1998;7(6):414–9.Walker SE. Modulation of hormones in the treatment of lupus. Am. J. Manag. Care. 2001 Oct;7(16 Suppl):S486–489.Jara LJ, Cruz-Cruz P, Saavedra M a, Medina G, García-Flores A, Angeles U, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann. N. Y. Acad. Sci. 2007 Sep;1110:297–304.Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007 Aug;1109:385–400.Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. Elsevier B.V.; 2012 May;11(6-7):A486–92.Steinberg AD, Steinberg BJ. Lupus disease activity associated with menstrual cycle. J. Rheumatol. 1985 Aug;12(4):816–7.Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002 Jan;11(3):175–80.Medeiros PB, Febrônio M V, Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus. 2009 Jan;18(1):38–43.Colangelo K, Haig S, Bonner A, Zelenietz C, Pope J. Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 2011 Apr;50(4):703–8http://hdl.handle.net/10818/9372256511TE0622760 Páginas.El Lupus Eritematoso Sistémico (LES) es un una enfermedad autoinmune con afectación multisistémica de gran variabilidad en su presentación y curso. Su diagnóstico se basa en características clínicas y de laboratorio en ausencia de otra enfermedad autoinmune que pueda explicar dichos hallazgos. Aunque el LES puede desarrollarse a cualquier edad, las mujeres en edad fértil son las principalmente afectadas. La relación mujer/hombre entre los 15 y 50 años de edad es > 8:1, mientras que llega a ser hasta 2:1 cuando ocurre durante la niñez o después de la menopausia. Esta prevalencia observada tanto en pacientes como en modelos animales, ha llevado a plantear la intervención de hormonas en el desarrollo y actividad de la misma. La relación entre el sistema neuroendocrino y el sistema inmune ha sido ampliamente demostrada. Comparten una red de conexiones mediadas por vías nerviosas, circuitos hormonales, interacciones celulares y humorales, así como una multitud de citoquinas, neuropéotidos y quemoquinas. De una interacción recíproca y modulada entre ambos sistemas depende el mantenimiento de la homeostasis. El desarrollo de una enfermedad multisistémica como el LES es el resultado del rompimiento de la misma. El LES se caracteriza por periodos de exacerbaciones y remisiones de la actividad de la enfermedad. Varios determinantes de este comportamiento han sido estudiados, sin que se haya esclarecido uno en especial; sin embargo, derivado de estudios observacionales de estados fisiológicos relacionados con aumento de actividad (por ejemplo, el embarazo) varios autores han demostrado la asociación con algunas hormonas. Entre las principales que han demostrado tener un efecto inmuno-modulador se encuentran el estrógeno y la prolactina.spaUniversidad de La SabanaEspecialización en Medicina InternaFacultad de MedicinaUniversidad de La SabanaIntellectum Repositorio Universidad de La SabanaProlatina -- InvestigacionesEstradiolLupus eritematoso cutáneo -- Piel -- EnfermedadesPerfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémicobachelorThesisTesis de especializaciónpublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/access_right/c_abf2LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/9372/2/license.txtf52a2cfd4df262e08e9b300d62c85cabMD52Elcie Carolina Aulestia Baldeón (Carta 1).pdfElcie Carolina Aulestia Baldeón (Carta 1).pdfapplication/pdf379802https://intellectum.unisabana.edu.co/bitstream/10818/9372/5/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20%28Carta%201%29.pdf8c7a67cd6fc21883c8de7aba8a3c39f0MD55Elcie Carolina Aulestia Baldeón (Carta 2).pdfElcie Carolina Aulestia Baldeón (Carta 2).pdfapplication/pdf159622https://intellectum.unisabana.edu.co/bitstream/10818/9372/6/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20%28Carta%202%29.pdf5d106558e1607a577e96767539702247MD56ORIGINALElcie Carolina Aulestia Baldeón FINAL.pdfElcie Carolina Aulestia Baldeón FINAL.pdfVer documento en PDFapplication/pdf1664375https://intellectum.unisabana.edu.co/bitstream/10818/9372/3/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20FINAL.pdf818da8cdd6d65332dcb9ff9bf061f758MD53TEXTElcie Carolina Aulestia Baldeón FINAL.pdf.txtElcie Carolina Aulestia Baldeón FINAL.pdf.txtExtracted Texttext/plain61https://intellectum.unisabana.edu.co/bitstream/10818/9372/4/Elcie%20Carolina%20Aulestia%20Balde%c3%b3n%20FINAL.pdf.txt173796950fb380beab4a5451d5eb6a18MD5410818/9372oai:intellectum.unisabana.edu.co:10818/93722019-08-13 15:36:17.997Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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

Publicaciones similares